Abstract: This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury. More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in reducing or inhibiting vessel wall hyperlasia and restoring vessel wall biocompatibility.

Abstract: Analysis of the huntington gene provides a method for identifying patients likely to respond to treatment of Huntington's disease with eicosapentaenoic acid, EPA.

Abstract: This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury. More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in reducing or inhibiting vessel wall hyperlasia and restoring vessel wall biocompatibility.

Abstract: Eicosapentaenoic acid (EPA) is used in the treatment of anorexia nervosa, bulimia and related clinical syndromes.

Abstract: The oral administration of an essential fatty acid, preferably eicosapentaenoic acid, at a defined purity together with an inhibitor of COX-1 or COX-2 or LOX or one or more of the FACL enzymes gives improved therapeutic results over administration of the fatty acid alone.

Abstract: The combined application of at least one essential fatty acid of the n-6 or n-3 series, optionally together with further essential fatty acid(s) of the n-6 or n-3 series, together with one or more homocysteine lowering agent. The homocysteine lowering agent is selected from vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6.

Abstract: This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in reducing or inhibiting vessel wall hyperplasia and restoring vessel wall biocompatibility.

Abstract: This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury. More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in reducing or inhibiting vessel wall hyperlasia and restoring vessel wall biocompatibility.

Abstract: An electrochromic display device having first and second electrodes, and a plurality of display electrodes, all immersed in a liquid electrolyte. Drive means act to first generate a potential difference between said first and second electrodes to cause a color species to be deposited on said first electrode and, thereafter, act to generate a potential difference between said first electrode and selected ones of said plurality of display electrodes to cause the color species to be transferred to the selected ones of said plurality of display electrodes. Heptyl viologen dibromide is suggested as one possible electrolyte.